Suppr超能文献

相似文献

2
Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing infections.
Korean J Intern Med. 2017 Jan;32(1):146-157. doi: 10.3904/kjim.2015.113. Epub 2016 Apr 20.
3
Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
J Antimicrob Chemother. 2006 Apr;57(4):780-3. doi: 10.1093/jac/dkl035. Epub 2006 Feb 21.
6
Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.
J Antimicrob Chemother. 2009 Apr;63(4):781-4. doi: 10.1093/jac/dkp028. Epub 2009 Feb 17.

引用本文的文献

1
Unveiling the impact: COVID-19's influence on bacterial resistance in the Kingdom of Bahrain.
World J Virol. 2025 Mar 25;14(1):100501. doi: 10.5501/wjv.v14.i1.100501.
3
Appropriateness of Empiric Initiation of Meropenem in the Intensive Care Unit as Determined by Internal Medicine Residents.
Antimicrob Steward Healthc Epidemiol. 2024 Oct 24;4(1):e185. doi: 10.1017/ash.2024.410. eCollection 2024.
5
Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities.
Biomedicines. 2023 Oct 30;11(11):2937. doi: 10.3390/biomedicines11112937.
7
Factors Associated with Extended-spectrum β-lactamase-producing Enterobacteria Isolated from Respiratory Samples.
Intern Med. 2023 Jul 15;62(14):2043-2050. doi: 10.2169/internalmedicine.0690-22. Epub 2022 Dec 7.
8
Clinical and demographic features associated with infections with extended-spectrum beta-lactamase-producing in a health system in Maine, 2017.
Antimicrob Steward Healthc Epidemiol. 2021 Jun 28;1(1):e7. doi: 10.1017/ash.2021.169. eCollection 2021.
9
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020).
Acute Med Surg. 2021 Aug 26;8(1):e659. doi: 10.1002/ams2.659. eCollection 2021 Jan-Dec.
10
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020).
J Intensive Care. 2021 Aug 25;9(1):53. doi: 10.1186/s40560-021-00555-7.

本文引用的文献

3
The latest threat in the war on antimicrobial resistance.
Lancet Infect Dis. 2010 Sep;10(9):578-9. doi: 10.1016/S1473-3099(10)70168-7. Epub 2010 Aug 10.
4
Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Int J Antimicrob Agents. 2010 Sep;36(3):284-7. doi: 10.1016/j.ijantimicag.2010.05.009. Epub 2010 Jun 30.
6
Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
Clin Microbiol Infect. 2010 Feb;16(2):147-51. doi: 10.1111/j.1469-0691.2009.02941.x. Epub 2009 Aug 18.
8
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Arch Intern Med. 2008 Sep 22;168(17):1897-902. doi: 10.1001/archinte.168.17.1897.
9
Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.
Lancet Infect Dis. 2008 Mar;8(3):159-66. doi: 10.1016/S1473-3099(08)70041-0.
10
Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):85-8. doi: 10.1007/s10096-007-0401-6. Epub 2007 Oct 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验